Louise C Ivers1, Isabelle J Hilaire2, Jessica E Teng3, Charles P Almazor2, J Gregory Jerome2, Ralph Ternier2, Jacques Boncy4, Josiane Buteau4, Megan B Murray5, Jason B Harris6, Molly F Franke7. 1. Department of Medicine, Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA; Department of Global Health and Social Medicine, Boston, MA, USA; Partners In Health, Boston, MA, USA. Electronic address: louise_ivers@hms.harvard.edu. 2. Zanmi Lasante, St Marc, Haiti. 3. Department of Medicine, Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA; Partners In Health, Boston, MA, USA. 4. Ministry of Health and Population, National Laboratory, Port-au-Prince, Haiti. 5. Department of Medicine, Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, USA; Department of Global Health and Social Medicine, Boston, MA, USA; Partners In Health, Boston, MA, USA. 6. Department of Pediatrics, Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. 7. Department of Global Health and Social Medicine, Boston, MA, USA; Partners In Health, Boston, MA, USA.
Abstract
BACKGROUND: Between April and June, 2012, a reactive cholera vaccination campaign was done in Haiti with an oral inactivated bivalent whole-cell vaccine. We aimed to assess the effectiveness of the vaccine in a case-control study and to assess the likelihood of bias in that study in a bias-indicator study. METHODS: Residents of Bocozel or Grand Saline who were eligible for the vaccination campaign (ie, age ≥12 months, not pregnant, and living in the region at the time of the vaccine campaign) were included. In the primary case-control study, cases had acute watery diarrhoea, sought treatment at one of three participating cholera treatment units, and had a stool sample positive for cholera by culture. For each case, four control individuals who did not seek treatment for acute watery diarrhoea were matched by location of residence, enrolment time (within 2 weeks of the case), and age (1-4 years, 5-15 years, and >15 years). Cases in the bias-indicator study were individuals with acute watery diarrhoea with a negative stool sample for cholera. Controls were selected in the same manner as in the primary case-control study. Trained staff used standard laboratory procedures to do rapid tests and stool cultures from study cases. Participants were interviewed to collect data on sociodemographic characteristics, risk factors for cholera, and self-reported vaccination. Data were analysed by conditional logistic regression, adjusting for matching factors. FINDINGS: From Oct 24, 2012, to March 9, 2014, 114 eligible individuals presented with acute watery diarrhoea and were enrolled, 25 of whom were subsequently excluded. 47 participants were analysed as cases in the vaccine effectiveness case-control study and 42 as cases in the bias-indicator study. 33 (70%) of 47 cholera cases self-reported vaccination versus 167 (89%) of 188 controls (vaccine effectiveness 63%, 95% CI 8-85). 27 (57%) of 47 cases had certified vaccination versus 147 (78%) of 188 controls (vaccine effectiveness 58%, 13-80). Neither self-reported nor verified vaccination was significantly associated with non-cholera diarrhoea (vaccine effectiveness 18%, 95% CI -208 to 78 by self-report and -21%, -238 to 57 by verified vaccination). INTERPRETATION: Bivalent whole-cell oral cholera vaccine effectively protected against cholera in Haiti from 4 months to 24 months after vaccination. Vaccination is an important component of efforts to control cholera epidemics. FUNDING: National Institutes of Health, Delivering Oral Vaccines Effectively project, and Department of Global Health and Social Medicine at Harvard Medical School.
BACKGROUND: Between April and June, 2012, a reactive cholera vaccination campaign was done in Haiti with an oral inactivated bivalent whole-cell vaccine. We aimed to assess the effectiveness of the vaccine in a case-control study and to assess the likelihood of bias in that study in a bias-indicator study. METHODS: Residents of Bocozel or Grand Saline who were eligible for the vaccination campaign (ie, age ≥12 months, not pregnant, and living in the region at the time of the vaccine campaign) were included. In the primary case-control study, cases had acute watery diarrhoea, sought treatment at one of three participating cholera treatment units, and had a stool sample positive for cholera by culture. For each case, four control individuals who did not seek treatment for acute watery diarrhoea were matched by location of residence, enrolment time (within 2 weeks of the case), and age (1-4 years, 5-15 years, and >15 years). Cases in the bias-indicator study were individuals with acute watery diarrhoea with a negative stool sample for cholera. Controls were selected in the same manner as in the primary case-control study. Trained staff used standard laboratory procedures to do rapid tests and stool cultures from study cases. Participants were interviewed to collect data on sociodemographic characteristics, risk factors for cholera, and self-reported vaccination. Data were analysed by conditional logistic regression, adjusting for matching factors. FINDINGS: From Oct 24, 2012, to March 9, 2014, 114 eligible individuals presented with acute watery diarrhoea and were enrolled, 25 of whom were subsequently excluded. 47 participants were analysed as cases in the vaccine effectiveness case-control study and 42 as cases in the bias-indicator study. 33 (70%) of 47 cholera cases self-reported vaccination versus 167 (89%) of 188 controls (vaccine effectiveness 63%, 95% CI 8-85). 27 (57%) of 47 cases had certified vaccination versus 147 (78%) of 188 controls (vaccine effectiveness 58%, 13-80). Neither self-reported nor verified vaccination was significantly associated with non-cholera diarrhoea (vaccine effectiveness 18%, 95% CI -208 to 78 by self-report and -21%, -238 to 57 by verified vaccination). INTERPRETATION: Bivalent whole-cell oral cholera vaccine effectively protected against cholera in Haiti from 4 months to 24 months after vaccination. Vaccination is an important component of efforts to control cholera epidemics. FUNDING: National Institutes of Health, Delivering Oral Vaccines Effectively project, and Department of Global Health and Social Medicine at Harvard Medical School.
Authors: Michael Emch; Mohammad Ali; Jin-Kyung Park; Mohammad Yunus; David A Sack; John D Clemens Journal: Int J Epidemiol Date: 2006-05-24 Impact factor: 7.196
Authors: D N Taylor; V Cárdenas; J L Sanchez; R E Bégué; R Gilman; C Bautista; J Perez; R Puga; A Gaillour; R Meza; P Echeverria; J Sadoff Journal: J Infect Dis Date: 2000-05-15 Impact factor: 5.226
Authors: Dipika Sur; Anna Lena Lopez; Suman Kanungo; Allison Paisley; Byomkesh Manna; Mohammad Ali; Swapan K Niyogi; Jin Kyung Park; Banawarilal Sarkar; Mahesh K Puri; Deok Ryun Kim; Jacqueline L Deen; Jan Holmgren; Rodney Carbis; Raman Rao; Thu Van Nguyen; Allan Donner; Nirmal K Ganguly; G Balakrish Nair; Sujit K Bhattacharya; John D Clemens Journal: Lancet Date: 2009-10-08 Impact factor: 79.321
Authors: Sujit K Bhattacharya; Dipika Sur; Mohammad Ali; Suman Kanungo; Young Ae You; Byomkesh Manna; Binod Sah; Swapan K Niyogi; Jin Kyung Park; Banwarilal Sarkar; Mahesh K Puri; Deok Ryun Kim; Jacqueline L Deen; Jan Holmgren; Rodney Carbis; Mandeep Singh Dhingra; Allan Donner; G Balakrish Nair; Anna Lena Lopez; Thomas F Wierzba; John D Clemens Journal: Lancet Infect Dis Date: 2013-10-18 Impact factor: 25.071
Authors: Richelle C Charles; Isabelle J Hilaire; Leslie M Mayo-Smith; Jessica E Teng; J Gregory Jerome; Molly F Franke; Amit Saha; Yanan Yu; Paul Kováč; Stephen B Calderwood; Edward T Ryan; Regina C LaRocque; Charles P Almazor; Firdausi Qadri; Louise C Ivers; Jason B Harris Journal: PLoS Negl Trop Dis Date: 2014-05-01
Authors: Francisco J Luquero; Lise Grout; Iza Ciglenecki; Keita Sakoba; Bala Traore; Melat Heile; Alpha Amadou Diallo; Christian Itama; Anne-Laure Page; Marie-Laure Quilici; Martin A Mengel; Jose Maria Eiros; Micaela Serafini; Dominique Legros; Rebecca F Grais Journal: N Engl J Med Date: 2014-05-29 Impact factor: 91.245
Authors: Lana Childs; Jeannot François; Alina Choudhury; Kathleen Wannemuehler; Amber Dismer; Terri B Hyde; Catherine Y Yen; Kashmira A Date; Stanley Juin; Mark A Katz; Erica Felker Kantor; Janell Routh; Melissa Etheart; Tracie Wright; Paul Adrien; Rania A Tohme Journal: Am J Trop Med Hyg Date: 2016-10-31 Impact factor: 2.345
Authors: Karine Sévère; Vanessa Rouzier; Stravinsky Benedict Anglade; Claudin Bertil; Patrice Joseph; Alexandra Deroncelay; Marie Marcelle Mabou; Peter F Wright; Florence Duperval Guillaume; Jean William Pape Journal: Am J Trop Med Hyg Date: 2016-02-29 Impact factor: 2.345
Authors: Molly F Franke; J Gregory Jerome; Wilfredo R Matias; Ralph Ternier; Isabelle J Hilaire; Jason B Harris; Louise C Ivers Journal: Vaccine Date: 2017-09-12 Impact factor: 3.641